Nausea Medicine Market Synopsis:
Nausea Medicine Market Size Was Valued at USD 2.8 Billion in 2023, and is Projected to Reach USD 4.3 Billion by 2032, Growing at a CAGR of 6.3% from 2024-2032.
The global nausea medicine market has lot of opportunities for growth as there is rising incidence of GID, chemotherapy-induced nausea, and motion sickness. Such situations have increased the need for good antiemetic drugs, these may be prescription ones or OTC. The market is underpinned by the development in pharmaceutical dosage forms and increasing consciousness regarding treatment of nausea particularly in developing nations.
One of the major application areas is to treat nausea and vomiting arising from chemotherapy & radiation therapy and this market is currently attributed by brands having antiemetic drugs major pharmaceutical players are also investing their resources for new drug discovery. Also, market diversification is facilitated by the increased popularity of natural remedies and other forms of complimentary therapies. New ventures in the administration and health care policies level, associated with improved accessibility of anti-nausea solutions, are also substantiating market growth.
It also threatens to suffer some negative impacts that may limit its growth, including mediations side effects and high development costs. Alternatively, there are opportunities in the form of unexploited markets within the developing world and the advances towards utilization of personalized medicine models. The statistics, the advances in combination drugs, and targeted therapies are believed to exert a positive impact on the market in the future.
Nausea Medicine Market Trend Analysis:
Rising Demand for Plant-Based and Natural Remedies
- The latest innovation that is prevailing in the nausea medicine market is related to plant-based and natural remedies. Natural remedies such as ginger, peppermint, and chamomile have received tremendous support from many consumers since they are effective and have little or no side effects to synthetic chemicals. This change is driven even more by increase in awareness by consumers of healthy product usage and natural cures leading to more pharmaceutical companies to engage in research to produce products from plants.
Growth of Personalized Medicine in Nausea Management
- Personalized medicine is gradually integrating into the nausea medicine market, especially drugs for anti-chemotherapy-nausea and other particular diseases. Genomic markers allow targeted therapies to be as effective as possible while causing the least side effects possible. This trend is especially important in the field of oncology, and is viewed to be a large factor in the continued development of anti-nausea drugs.
Nausea Medicine Market Segment Analysis:
Nausea Medicine Market is Segmented on the basis of drug class, route of administration, distribution channel, and region
By Drug Class, Antihistamines segment is expected to dominate the market during the forecast period
- The market is divided by drug type into antihistamines, anticholinergics, serotonin antagonists, dopamine antagonists, cannabinoids, and other drugs for the treatment of nausea. For motion sickness and other mild nausea, antihistamines and anticholinergics are often prescribed, while serotonin–antagonists and dopamine antagonists are used for nausea caused by chemotherapy, radiotherapy or surgery. Obviously, cannabinoids are turning out to be an opportunity in conjunction with the conventional therapy failure especially in oncology care. This market segmentation shows that the market is actually very divided due to the unlimited needs patients have for treatments, regarding many illnesses.
By Distribution Channel, Retail Pharmacies segment expected to held the largest share
- On the basis of distribution channel, the nausea medicine market can be categorized as retail pharmacy, hospital pharmacy, online pharmacy and others, they have their own customers or different requirements. Retail pharmacy accounts for a major share of ‘the’ total market because they are very numerous and consumers can easily obtain OTC or prescription anti-nausea remedies. Ambulatory pharmacies are also very critical in the delivery of specialty services especially to patients in chemotheraphy, post-operation patients and many others. The home delivery services are swiftly receiving an optimistic response and the web-based businesses for all healthcare related products are receiving a positive response. Specialized clinics and wellness centers are other points of access, that affect the growth of the market through their availability of niche products and customer-specific services.
Nausea Medicine Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- North America is anticipated to have the largest market share of the nausea medicine market during the forecast period due to growing cases of GID, well-developed healthcare systems, and early and faster adaptation of new remedial treatments. A large concentration of the population in the region receives cancer treatment through the use of chemotherapy and radiation therapy, which ups the need for good anti-nausea medication. Further, research and development undertaken by the leading pharmaceutical firms and a constructive government healthcare policy put North America in a commanding position of this market.
Active Key Players in the Nausea Medicine Market
- Novartis AG (Switzerland)
- Merck & Co., Inc. (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- GlaxoSmithKline PLC (UK)
- Pfizer Inc. (US)
- Sanofi S.A. (France)
- Mylan NV (US)
- AstraZeneca (UK)
- Cipla Inc. (India), and Others Active Players.
Key Industry Development:
In January 2023, Helsinn Group, a global biopharma company, and Immedica Pharma AB, a pharmaceutical company specializing in rare and specialty care products, announced an exclusive long-term license and distribution agreement for two cancer supportive care products in core European markets. The agreement covered AKYNZEO (Netupitant-Palonosetron fixed combination) and AKYNZEO (Palonosetron), both indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV).
|
Nausea Medicine Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 2.8 Billion |
|
Forecast Period 2024-32 CAGR: |
6.3% |
Market Size in 2032: |
USD 4.3 Billion |
|
Segments Covered: |
By Drug Class |
|
|
|
By Route of Administration |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Nausea Medicine Market by Drug Class (2018-2032)
4.1 Nausea Medicine Market Snapshot and Growth Engine
4.2 Market Overview
4.3 Antihistamines
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
4.3.3 Key Market Trends, Growth Factors, and Opportunities
4.3.4 Geographic Segmentation Analysis
4.4 Anticholinergics
4.5 Serotonin Antagonists
4.6 Dopamine Antagonists
4.7 Cannabinoids
4.8 Others
Chapter 5: Nausea Medicine Market by Route of Administration (2018-2032)
5.1 Nausea Medicine Market Snapshot and Growth Engine
5.2 Market Overview
5.3 Oral
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
5.3.3 Key Market Trends, Growth Factors, and Opportunities
5.3.4 Geographic Segmentation Analysis
5.4 Injectable
5.5 Transdermal
5.6 Rectal
5.7 Others
Chapter 6: Nausea Medicine Market by Distribution Channel (2018-2032)
6.1 Nausea Medicine Market Snapshot and Growth Engine
6.2 Market Overview
6.3 Retail Pharmacies
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
6.3.3 Key Market Trends, Growth Factors, and Opportunities
6.3.4 Geographic Segmentation Analysis
6.4 Hospital Pharmacies
6.5 Online Pharmacies
6.6 Others
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Nausea Medicine Market Share by Manufacturer (2024)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 NOVARTIS AG (SWITZERLAND)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 MERCK & CO. INC. (US)
7.4 F. HOFFMANN-LA ROCHE LTD (SWITZERLAND)
7.5 GLAXOSMITHKLINE PLC (UK)
7.6 PFIZER INC. (US)
7.7 SANOFI S.A. (FRANCE)
7.8 MYLAN NV (US)
7.9 ASTRAZENECA (UK)
7.10 CIPLA INC. (INDIA)
7.11 OTHER ACTIVE PLAYERS.
Chapter 8: Global Nausea Medicine Market By Region
8.1 Overview
8.2. North America Nausea Medicine Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size by Drug Class
8.2.4.1 Antihistamines
8.2.4.2 Anticholinergics
8.2.4.3 Serotonin Antagonists
8.2.4.4 Dopamine Antagonists
8.2.4.5 Cannabinoids
8.2.4.6 Others
8.2.5 Historic and Forecasted Market Size by Route of Administration
8.2.5.1 Oral
8.2.5.2 Injectable
8.2.5.3 Transdermal
8.2.5.4 Rectal
8.2.5.5 Others
8.2.6 Historic and Forecasted Market Size by Distribution Channel
8.2.6.1 Retail Pharmacies
8.2.6.2 Hospital Pharmacies
8.2.6.3 Online Pharmacies
8.2.6.4 Others
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Nausea Medicine Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size by Drug Class
8.3.4.1 Antihistamines
8.3.4.2 Anticholinergics
8.3.4.3 Serotonin Antagonists
8.3.4.4 Dopamine Antagonists
8.3.4.5 Cannabinoids
8.3.4.6 Others
8.3.5 Historic and Forecasted Market Size by Route of Administration
8.3.5.1 Oral
8.3.5.2 Injectable
8.3.5.3 Transdermal
8.3.5.4 Rectal
8.3.5.5 Others
8.3.6 Historic and Forecasted Market Size by Distribution Channel
8.3.6.1 Retail Pharmacies
8.3.6.2 Hospital Pharmacies
8.3.6.3 Online Pharmacies
8.3.6.4 Others
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Nausea Medicine Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size by Drug Class
8.4.4.1 Antihistamines
8.4.4.2 Anticholinergics
8.4.4.3 Serotonin Antagonists
8.4.4.4 Dopamine Antagonists
8.4.4.5 Cannabinoids
8.4.4.6 Others
8.4.5 Historic and Forecasted Market Size by Route of Administration
8.4.5.1 Oral
8.4.5.2 Injectable
8.4.5.3 Transdermal
8.4.5.4 Rectal
8.4.5.5 Others
8.4.6 Historic and Forecasted Market Size by Distribution Channel
8.4.6.1 Retail Pharmacies
8.4.6.2 Hospital Pharmacies
8.4.6.3 Online Pharmacies
8.4.6.4 Others
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Nausea Medicine Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size by Drug Class
8.5.4.1 Antihistamines
8.5.4.2 Anticholinergics
8.5.4.3 Serotonin Antagonists
8.5.4.4 Dopamine Antagonists
8.5.4.5 Cannabinoids
8.5.4.6 Others
8.5.5 Historic and Forecasted Market Size by Route of Administration
8.5.5.1 Oral
8.5.5.2 Injectable
8.5.5.3 Transdermal
8.5.5.4 Rectal
8.5.5.5 Others
8.5.6 Historic and Forecasted Market Size by Distribution Channel
8.5.6.1 Retail Pharmacies
8.5.6.2 Hospital Pharmacies
8.5.6.3 Online Pharmacies
8.5.6.4 Others
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Nausea Medicine Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size by Drug Class
8.6.4.1 Antihistamines
8.6.4.2 Anticholinergics
8.6.4.3 Serotonin Antagonists
8.6.4.4 Dopamine Antagonists
8.6.4.5 Cannabinoids
8.6.4.6 Others
8.6.5 Historic and Forecasted Market Size by Route of Administration
8.6.5.1 Oral
8.6.5.2 Injectable
8.6.5.3 Transdermal
8.6.5.4 Rectal
8.6.5.5 Others
8.6.6 Historic and Forecasted Market Size by Distribution Channel
8.6.6.1 Retail Pharmacies
8.6.6.2 Hospital Pharmacies
8.6.6.3 Online Pharmacies
8.6.6.4 Others
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Nausea Medicine Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size by Drug Class
8.7.4.1 Antihistamines
8.7.4.2 Anticholinergics
8.7.4.3 Serotonin Antagonists
8.7.4.4 Dopamine Antagonists
8.7.4.5 Cannabinoids
8.7.4.6 Others
8.7.5 Historic and Forecasted Market Size by Route of Administration
8.7.5.1 Oral
8.7.5.2 Injectable
8.7.5.3 Transdermal
8.7.5.4 Rectal
8.7.5.5 Others
8.7.6 Historic and Forecasted Market Size by Distribution Channel
8.7.6.1 Retail Pharmacies
8.7.6.2 Hospital Pharmacies
8.7.6.3 Online Pharmacies
8.7.6.4 Others
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Nausea Medicine Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 2.8 Billion |
|
Forecast Period 2024-32 CAGR: |
6.3% |
Market Size in 2032: |
USD 4.3 Billion |
|
Segments Covered: |
By Drug Class |
|
|
|
By Route of Administration |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Frequently Asked Questions :
The forecast period in the Nausea Medicine Market research report is 2024-2032.
Novartis AG (Switzerland), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline PLC (UK), Pfizer Inc. (US), Sanofi S.A. (France), Mylan NV (US), AstraZeneca (UK), Cipla Inc. (India), and Others Active Players.
The Nausea Medicine Market is segmented into By Drug Class, By Route of Administration, By Distribution Channel and region. By Drug Class (Antihistamines, Anticholinergics, Serotonin Antagonists, Dopamine Antagonists, Cannabinoids, and Others), By Route of Administration (Oral, Injectable, Transdermal, Rectal, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others). By region, it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Russia; Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; The Netherlands; Italy; Spain; Rest of Western Europe), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).
Nausea medicine, also known as antiemetics, refers to a class of drugs designed to prevent or alleviate nausea and vomiting caused by various conditions, including motion sickness, gastrointestinal disorders, chemotherapy, or pregnancy. These medications function by targeting specific pathways in the brain and gastrointestinal tract that trigger nausea, such as dopamine, serotonin, and histamine receptors. Commonly used nausea medicines include over-the-counter remedies like antihistamines and prescription medications like serotonin receptor antagonists. By effectively managing symptoms, nausea medicines play a critical role in improving the quality of life for patients experiencing acute or chronic nausea.
Nausea Medicine Market Size Was Valued at USD 2.8 Billion in 2023, and is Projected to Reach USD 4.3 Billion by 2032, Growing at a CAGR of 6.3% from 2024-2032.
